Oncolytic Herpes Simplex Virus 1 (HSV-1) vectors: Increasing treatment efficacy and range through strategic virus design

Drugs of the Future

Volumn 35, Issue 3, 2010, Pages 183-195

  Carson, J ^a   Haddad, D ^a,b   Bressman, M ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

G 207; G 47; G 47 DELTA; HSV 1716; NV 1020; NV 1034; NV 1042; NV 1066; ONCOLYTIC HERPES VIRUS; ONCOVEX; UNCLASSIFIED DRUG;

BRAIN CANCER; CANCER CELL DESTRUCTION; CANCER MODEL; CANCER TISSUE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE DELETION; GLIOMA; HERPES SIMPLEX VIRUS 1; HUMAN; LIFE CYCLE; LIVER CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOUTH CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SQUAMOUS CELL CARCINOMA; TISSUE SPECIFICITY; UNSPECIFIED SIDE EFFECT; VIROGENESIS; VIRUS ENTRY; VIRUS GENE; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS VIRULENCE;

EID: 84952989995     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.03.1470166     Document Type: Review

References (169)

1. Dock, G. Influence of complicating diseases upon leukemia. Am J Med Sci 1904, 127: 563.
2. Kovacs, F. Wien klin Wochenschr 1893, 39: 701.
3. Sinkovics, J., Horvath, J. New developments in the virus therapy of cancer: A historical review. Intervirology 1993, 36(4): 193-214. (Pubitemid 24054577)
4. Levaditi, C., Nicolau, S. Affinite du virus herpetique pour les neoplasmes epitheliaux. Comptes Rendus Soc Biol 1922, 87: 498-500.
5. Southam, C.M., Moore, A.E. Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus. Cancer 1952, 5(5): 1025-34.
6. Moore, A.E. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 1949, 2(3): 525-34.
7. Moore, A.E. Inhibition of growth of five transplantable mouse tumors by the virus of Russian Far East encephalitis. Cancer 1951, 4(2): 375-82.
8. Moore, A.E., O'Connor, S. Further studies on the destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer 1950, 3(5): 886-90.
9. Hoster, H.A., Zanes, R.P. Jr., Von, H.E. Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report. Cancer Res 1949, 9(8): 473-80.
10. Vaha-Koskela, M.J., Heikkila, J.E., Hinkkanen, A.E. Oncolytic viruses in cancer therapy. Cancer Lett 2007, 254(2): 178-216.
11. Asada, T. Treatment of human cancer with mumps virus. Cancer 1974, 34(6): 1907-28.
12. Okuno, Y., Asada, T., Yamanishi, K. et al. Studies on the use of mumps virus for treatment of human cancer. Biken J 1978, 21(2): 37-49.
13. Smith, R.R., Huebner, R.J., Rowe, W.P., Schatten, W.E., Thomas, L.B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956, 9(6): 1211-8.
14. Mettler, N.E., Clarke, D.H., Casals, J. Virus inoculation in mice bearing Ehrlich ascitic tumors: Antigen production and tumor regression. Infect Immun 1982, 37(1): 23-7. (Pubitemid 12095176)
15. Hersey, P., Coates, A.S., McCarthy, W.H. et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol 2002, 20(20): 4181-90. (Pubitemid 35191020)
16. Roizman, B., Knipe, D., Whitley, R. Herpes simplex viruses. In: Fields Virology, 5th Ed. D.M. Knipe, P. Howley (Eds). Philadelphia: Lippincott Williams & Wiilkins, 2007, 2501-602.
17. Delman, K., Bennett, J.J., Zager, J.S. et al. Effects of preexising immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000, 11(18): 2465-72.
18. Lambright, E.S., Kang, E.H., Force, S. et al. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Mol Ther 2000, 2(4): 387-93.
19. Chahlavi, A., Rabkin, S., Todo, T., Sundaresan, P., Martuza, R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999, 6(10): 1751-8. (Pubitemid 29485951)
20. Yang, C.T., Song, J., Bu, X. et al. Herpes simplex virus type-1 infection upregulates cellular promoters and telomerase activity in both tumor and nontumor human cells. Gene Ther 2003, 10(17): 1494-502. (Pubitemid 36992161)
21. Coen, D.M., Kosz-Vnenchak, M., Jacobson, J.C. et al. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A 1989, 86(12): 4736-40. (Pubitemid 19164624)
22. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., Coen, D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252(5007): 854-6. (Pubitemid 121000529)
23. Goldstein, D.J., Weller, S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988, 62(1): 196-205.
24. Goldstein, D.J., Weller, S.K. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 1988, 166(1): 41-51.
25. Jacobson, J.C., Leib, D.A., Goldstein, D.J. et al. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 1989, 173(1): 276-83.
26. Markert, J.M., Malick, A., Coen, D.M., Martuza, R.L. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993, 32(4): 597-603.
27. He, B., Gross, M., Roizman, B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A 1997, 94(3): 843-8.
28. He, B., Gross, M., Roizman, B. The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells. J Biol Chem 1998, 273(33): 20737-43.
29. Smith, K.D., Mezhir, J.J., Bickenbach, K. et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 2006, 80(3): 1110-20.
30. Veerapong, J., Bickenbach, K.A., Shao, M.Y. et al. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 2007, 67(17): 8301-6.
31. Detta, A., Harland, J., Hanif, I., Brown, S.M., Cruickshank, G. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J Gene Med 2003, 5(8): 681-9.
32. Benencia, F., Courreges, M.C., Conejo-Garcia, J.R. et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005, 12(5): 789-802. (Pubitemid 41614474)
33. Yazaki, T., Manz, H.J., Rabkin, S.D., Martuza, R.L. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995, 55(21): 4752-6.
34. Kramm, C.M., Chase, M., Herrlinger, U. et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997, 8(17): 2057-68. (Pubitemid 28072576)
35. Mavromara-Nazos, P., Ackermann, M., Roizman, B. Construction and properties of a viable herpes simplex virus 1 recombinant lacking coding sequences of the alpha 47 gene. J Virol 1986, 60(2): 807-12. (Pubitemid 17174932)
36. Todo, T., Martuza, R.L., Rabkin, S.D., Johnson, P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 2001, 98(11): 6396-401. (Pubitemid 32488248)
37. Takakuwa, H., Goshima, F., Nozawa, N. et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003, 148(4): 813-25. (Pubitemid 36425166)
38. Ogawa, F., Takaoka, H., Iwai, S., Aota, K., Yura, Y. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Anticancer Res 2008, 28(6A): 3637-45.
39. Luo, C., Mori, I., Goshima, F. et al. Replication-competent, oncolytic herpes simplex virus type 1 mutants Induce a bystander effect following ganciclovir treatment. J Gene Med 2007, 9(10): 875-83. (Pubitemid 47543254)
40. Fujimoto, Y., Mizuno, T., Sugiura, S. et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 2006, 126(10): 1115-7.
41. Kohno, S., Luo, C., Goshima, F., Nishiyama, Y., Sata, T., Ono, Y. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer. Urology 2005, 66(5): 1116-21. (Pubitemid 41587186)
42. Sugiura, S., Goshima, F., Takakuwa, H., Sata, T., Nakashima, T., Nishiyama, Y. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses. Otolaryngol Head Neck Surg 2004, 130(4): 470-8. (Pubitemid 38509540)
43. Kimata, H., Takakuwa, H., Goshima, F. et al. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 2003, 50(52): 961-6. (Pubitemid 36723820)
44. Nawa, A., Luo, C., Zhang, L. et al. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr Gene Ther 2008, 8(3): 208-21.
45. Teshigahara, O., Goshima, F., Takao, K. et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol 2004, 85(1): 42-7. (Pubitemid 38036739)
46. Watanabe, D., Goshima, F., Mori, I., Tamada, Y., Matsumoto, Y., Nishiyama, Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci 2008, 50(3): 185-96.
47. Kohno, S.I., Luo, C., Nawa, A. et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther 2007, 14(11): 918-26. (Pubitemid 47558955)
48. Nakao, A., Takeda, S., Shimoyama, S. et al. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr Cancer Drug Targets 2007, 7(2): 169-74.
49. Kimata, H., Imai, T., Kikumori, T. et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 2006, 13(8): 1078-84.
50. Berkowitz, C., Moyal, M., Rosen-Wolff, A., Darai, G., Becker, Y. Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice. Arch Virol 1994, 134(1-2): 73-83.
51. Ushijima, Y., Goshima, F., Kimura, H., Nishiyama, Y. Herpes simplex virus type 2 tegument protein UL56 relocalizes ubiquitin ligase Nedd4 and has a role in transport and/or release of virions. Virol J 2009, 6: 168.
52. Koshizuka, T., Goshima, F., Takakuwa, H. et al. Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J Virol 2002, 76(13): 6718-28.
53. Rampling, R., Cruickshank, G., Papanastassiou, V. et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000, 7(10): 859-66. (Pubitemid 30303583)
54. Kemeny, N., Brown, K., Covey, A. et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006, 17(12): 1214-24. (Pubitemid 44975138)
55. Fong, Y., Kim, T., Bhargava, A. et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009, 17(2): 389-94.
56. Mace, A.T., Ganly, I., Soutar, D.S., Brown, S.M. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 2008, 30(8): 1045-51.
57. Harrow, S., Papanastassiou, V., Harland, J. et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 2004, 11(22): 1648-58. (Pubitemid 39530101)
58. Papanastassiou, V., Rampling, R., Fraser, M. et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Gene Ther 2002, 9(6): 398-406. (Pubitemid 34414038)
59. MacKie, R.M., Stewart, B., Brown, S.M. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001, 357(9255): 525-6. (Pubitemid 32173591)
60. Markert, J.M., Medlock, M.D., Rabkin, S.D. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 2000, 7(10): 867-74.
61. Huang, Y.Y., Yu, Z., Lin, S.F., LI, S., Fong, Y., Wong, R.J. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 2007, 92(5): 1965-70. (Pubitemid 46043655)
62. Yu, Z., Li, S., Huang, Y.Y., Fong, Y., Wong, R.J. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma. Cancer Gene Ther 2007, 14(8): 738-47.
63. Laquerre, S., Argnani, R., Anderson, D.B., Zucchini, S., Manservigi, R., Glorioso, J.C. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread. J Virol 1998, 72(7): 6119-30.
64. Zhou, G., Ye, G.J., Debinski, W., Roizman, B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A 2002, 99(23): 15124-9. (Pubitemid 35334620)
65. Menotti, L., Cerretani, A., Campadelli-Fiume, G. A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 2006, 80(11): 5531-9.
66. Conner, J., Braidwood, L., Brown, S.M. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: Redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Gene Ther 2008, 15(24): 1579-92.
67. Menotti, L., Nicoletti, G., Gatta, V. et al. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci U S A 2009, 106(22): 9039-44.
68. Reinblatt, M., Pin, R.H., Fong, Y. Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer. Surgery 2004, 136(3): 579-84.
69. Pin, R.H., Reinblatt, M., Fong, Y. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma. Ann Surg 2004, 240(4): 659-65.
70. Kambara, H., Okano, H., Chiocca, E.A., Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005, 65(7): 2832-9.
71. Kanai, R., Tomita, H., Shinoda, A. et al. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther 2006, 13(2): 106-16. (Pubitemid 43039903)
72. Kanai, R., Eguchi, K., Takahashi, M. et al. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer-Expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy. J Gene Med 2006, 8(11): 1329-40. (Pubitemid 44782512)
73. Kasuya, H., Pawlik, T.M., Mullen, J.T. et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004, 64(7): 2561-7. (Pubitemid 38523913)
74. Lee, C.Y., Bu, L.X., Rennie, P.S., Jia, W.W. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells. Cancer Gene Ther 2007, 14(7): 652-60.
75. Chun, Y.S., Adusumilli, P.S., Fong, Y. Employing tumor hypoxia for oncolytic therapy in breast cancer. J Mammary Gland Biol Neoplasia 2005, 10(4): 311-8. (Pubitemid 44256411)
76. Reinblatt, M., Pin, R.H., Federoff, H.J., Fong, Y. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann Surg 2004, 239(6): 892-9. (Pubitemid 38669440)
77. DeLuca, N.A., McCarthy, A.M., Schaffer, P.A. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985, 56(2): 558-70.
78. Kuroda, T., Rabkin, S.D., Martuza, R.L. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006, 66(20): 10127-35.
79. Pan, W., Bodempudi, V., Esfandyari, T., Farassati, F. Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1. PLoS ONE 2009, 4(8): e6514.
80. Lee, C.Y., Rennie, P.S., Jia, W.W. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res 2009, 15(16): 5126-35.
81. Jain, R.K. The next frontier of molecular medicine: Delivery of therapeutics. Nat Med 1998, 4(6): 655-7.
82. Mok, W., Stylianopoulos, T., Boucher, Y., Jain, R.K. Mathematical modeling of herpes simplex virus distribution in solid tumors: Implications for cancer gene therapy. Clin Cancer Res 2009, 15(7): 2352-60.
83. Fu, X., Tao, L., Jin, A., Vile, R., Brenner, M.K., Zhang, X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003, 7(6): 748-54.
84. Hoffmann, D., Bayer, W., Wildner, O. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis. Hum Gene Ther 2007, 18(5): 435-50.
85. Nakamori, M., Fu, X., Meng, F. et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003, 9(7): 2727-33.
86. Nakamori, M., Fu, X., Rousseau, R., Chen, S.Y., Zhang, X. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 2004, 9(5): 658-65. (Pubitemid 38660418)
87. Nakamori, M., Fu, X., Pettaway, C.A., Zhang, X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004, 60(1): 53-60. (Pubitemid 38669229)
88. Israyelyan, A.H., Melancon, J.M., Lomax, L.G. et al. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells. Hum Gene Ther 2007, 18(5): 457-73.
89. Fu, X., Nakamori, M., Tao, L., Amato, R., Zhang, X. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol 2007, 30(6): 1561-7.
90. Israyelyan, A., Chouljenko, V.N., Baghian, A., David, A.T., Kearney, M.T., Kousoulas, K.G. Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice. Virol J 2008, 5: 68. (Pubitemid 351962614)
91. Andreansky, S., He, B., van Cott, J. et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998, 5(1): 121-30. (Pubitemid 28045078)
92. Bennett, J.J., Malhotra, S., Wong, R.J. et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann Surg 2001, 233(6): 819-26. (Pubitemid 32494563)
93. Jarnagin, W.R., Zager, J.S., Klimstra, D. et al. Neoadjuvant treatment of hepatic malignancy: An oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection. Cancer Gene Ther 2003, 10(3): 215-23. (Pubitemid 36348683)
94. Varghese, S., Rabkin, S.D., Liu, R., Nielsen, P.G., Ipe, T., Martuza, R.L. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006, 13(3): 253-65. (Pubitemid 43255762)
95. Han, Z.Q., Assenberg, M., Liu, B.L. et al. Development of a second-generation oncolytic herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med 2007, 9(2): 99-106.
96. Wong, R.J., Chan, M.K., Yu, Z. et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interieukin 12. Clin Cancer Res 2004, 10(1, Pt. 1): 251-9. (Pubitemid 38114187)
97. Wong, R.J., Patel, S.G., Kim, S. et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001, 12(3): 253-65. (Pubitemid 32163897)
98. Todo, T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr 2008, 2(3): 208-13.
99. DeRubertis, B.G., Stiles, B.M., Bhargava, A. et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther 2007, 14(6): 590-7. (Pubitemid 46788334)
100. Malhotra, S., Kim, T., Zager, J. et al. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery 2007, 141(4): 520-9. (Pubitemid 46441313)
101. Varghese, S., Rabkin, S.D., Nielsen, P.G., Wang, W., Martuza, R.L. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 2006, 12(9): 2919-27. (Pubitemid 43752135)
102. Simpson, G.R., Han, Z., Liu, B., Wang, Y., Campbell, G., Coffin, R.S. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006, 66(9): 4835-42.
103. Coffin, R.S., Liu, B., Ziqun, H. et al. OncoVEX: A family of oncolytic herpes simplex vlmses optimised for therapeutic use. Mol Ther 2006, 13(Suppl. 1): Abst 166.
104. Aghi, M., Rabkin, S.D., Martuza, R.L. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin- derived peptide. Cancer Res 2007, 67(2): 440-4. (Pubitemid 46192178)
105. Liu, T.C., Zhang, T., Fukuhara, H. et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 2006, 14(6): 789-97. (Pubitemid 44752718)
106. Mullen, J.T., Donahue, J.M., Chandrasekhar, S. et al. Oncolysis by viral replication and inhibition of oncogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer 2004, 101(4): 869-77. (Pubitemid 39030946)
107. Yang, C.T., Lin, Y.C., Lin, C.L. et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. Anticancer Res 2005, 25(3B): 2049-54.
108. Liu, T.C., Zhang, T., Fukuhara, H. et al. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res 2006, 12(22): 6791-9. (Pubitemid 44876849)
109. Mahller, Y.Y., Vaikunth, S.S., Ripberger, M.C. et al. Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008, 68(4): 1170-9.
110. Mok, W., Boucher, Y., Jain, R.K. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007, 67(22): 10664-8. (Pubitemid 350145891)
111. Todo, T., Rabkin, S.D., Martuza, R.L. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther 2000, 7(6): 939-46.
112. Pawlik, T.M., Nakamura, H., Mullen, J.T. et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002, 95(5): 1171-81.
113. Tyminski, E., Leroy, S., Terada, K. et al. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 2005, 65(15): 6850-7.
114. Currier, M.A., Gillespie, R.A., Sawtell, N.M. et al. Efficacy and safety of the oncolytic herpes simplex virus rRp4S0 alone and combined with cyclophosphamide. Mol Ther 2008, 16(5): 879-85.
115. Braidwood, L., Dunn, P.D., Hardy, S., Evans, T.R., Brown, S.M. Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy. Anticancer Res 2009, 29(6): 2159-66.
116. Ishida, D., Nawa, A., Tanino, T. et al. Enhanced cytotoxicity with a novel system combining the paclitaxel-2′-ethylcarbonate prodmg and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus. Cancer Lett 2010, 288(1): 17-27.
117. Nawa, A., Nozawa, N., Goshima, F. et al. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant 1n a mouse model. Gynecol Oncol 2003, 91(1): 81-8.
118. Watanabe, I., Kasuya, H., Nomura, N. et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol 2008, 61(5): 875-82.
119. Mandell, R.B., Mandell, L.Z., Link, C.J. Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999, 59(3): 661-8.
120. Boyd, M., Cunningham, S.H., Brown, M.M., Mairs, R.J., Wheldon, T.E. Noradrenaline transporter gene transfer for radiation cell kill by 1311 metaiodobenzylguanidine. Gene Ther 1999, 6(6): 1147-52.
121. Boyd, M., Mairs, R.J., Cunningham, S.H. et al. A gene therapy/targeted radiotherapy strategy for radiation cell kill by. J Gene Med 2001, 3(2): 165-72.
122. Quigg, M., Mairs, R.J., Brown, S.M. et al. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. Med Chem 2005, 1(5): 423-9.
123. Carroll, N.M., Chiocca, E.A., Takahashi, K., Tanabe, K.K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996, 224(3): 323-9; discussion 329-30.
124. Kulu, Y., Dorfman, J.D., Kuruppu, D. et al. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice. Cancer Gene Ther 2009, 16(4): 291-7.
125. Mahller, Y.Y., Rangwala, F., Ratner, N., Cripe, T.P. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer 2006, 46(7): 745-54.
126. Cullinan, A.E., Lindstrom, M.J., Sabet, S., Albert, D.M., Brandt, C.R. Evaluation of the antitumor effects of herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model. Curr Eye Res 2004, 29(2-3): 167-72.
127. Benencia, F., Courreges, M.C., Conejo-Garcia, J.R. et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005, 16(6): 765-78.
128. Kesari, S., Randazzo, B.P., Valyi-Nagy, T. et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 1995, 73(5): 636-48.
129. Randazzo, B.P., Bhat, M.G., Kesari, S., Fraser, N.W., Brown, S.M. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 1997, 108(6): 933-7.
130. Kelly, K.J., Wong, J., Fong, Y. Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs 2008, 17(7): 1105-13.
131. Neville, R.W., Stewart, G.A., Sutton, P.M., Taghizadeh, A., Trethewey, J. Anti-insulin serum, plasma insulin, and the hypoglycaemia of total pancreatectomy and partial hepatectomy in the rat. Br J Exp Pathol 1971, 52: 1-6.
132. Delman, K.A., Zager, J.S., Bhargava, A. et al. Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy. Hepatology 2004, 39(6): 1525-32.
133. Bennett, J.J., Delman, K.A., Burt, B.M. et al. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 2002, 9(11): 935-45.
134. Cozzi, P.J., Burke, P.B., Bhargav, A. et al. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 2002, 53(2): 95-100.
135. Wong, R.J., Kim, S.H., Joe, J.K., Shah, J.P., Johnson, P.A., Fong, Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001, 193(1): 12-21.
136. Kelsen, D., Karpeh, M., Schwartz, G. et al. Neoadjuvant therapy of high-risk gastric cancer: A phase 11 trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus Intravenous fluorouracil. J Clin Oncol 1999, 14: 1818-28.
137. McAuliffe, P.F., Jarnagin, W.R., Johnson, P., Delman, K.A., Federoff, H., Fong, Y. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000, 4(6): 580-8.
138. Zuber-Jerger, I., Geissler, M., Spangenberg, H.C., Mohr, L., Weizsacker, F., Blum, H.E. Local ablation of malignant lesions of the liver - Potential applications and limitations of the different methods. Zeit Gastroenterol 2004, 42(1): 31-8.
139. Song, T.J., Eisenberg, D.P., Adusumilli, P.S., Hezel, M., Fong, Y. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines. J Gastrointest Surg 2006, 10(4): 532-42.
140. Cinatl, J. Jr., Michaelis, M., Driever, P.H. et al. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia 2004, 6(6): 725-35.
141. Cozzi, P.J., Malhotra, S., McAuliffe, P. et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and NV1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001, 15(7): 1306-8.
142. Oyama, M., Ohigashi, T., Hoshi, M., Murai, M., Uyemura, K., Yazaki, T. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207. Jpn J Cancer Res 2000, 91(12): 1339-44.
143. Soudon, P., Stijns, M., Tremouroux-Wattiez, M., Vliers, A. Precocity of pulmonary vascular obstruction of Down's syndrome. Eur J Cardiol 1975, 2(4): 473-6.
144. Coukos, G., Makrigiannakis, A., Montas, S. et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000, 7(2): 275-83.
145. Schweizer, W., Tanner, S., Baer, H.U., Huber, A., Berchtold, R., Blumgart, L.H. [Diagnosis and therapy of liver injuries in the polytraumatized patient]. Helv Chir Acta 1989, 55: 597-612.
146. Kooby, D.A., Carew, J.F., Halterman, M.W. et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999, 13(11): 1325-34.
147. Passer, B.J., Wu, C.L., Wu, S., Rabkin, S.D., Martuza, R.L. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther 2009, 16(12): 1477-82.
148. Todo, T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 2008, 13: 2060-4.
149. Prabhakar, S., Messerli, S.M., Stemmer-Rachamimov, A.O. et al. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther 2007, 14(5): 460-7.
150. Fukuhara, H., Martuza, R.L., Rabkin, S.D., Ito, Y., Todo, T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res 2005, 11(21): 7886-90.
151. Liu, R., Martuza, R.L., Rabkin, S.D. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 2005, 12(8): 647-54.
152. Liu, R., Varghese, S., Rabkin, S.D. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 2005, 65(4): 1532-40.
153. Kolodkin-Gal, D., Edden, Y., Hartshtark, Z. et al. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther 2009, 16(7): 905-15.
154. Nicolo, M., Chiocca, E.A. Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants. Ophthalmic Res 1998, 30(1): 30-6. (Pubitemid 28043935)
155. James, R.D., Wilkinson, P.M., Belli, F., Welch, R., Cowan, R. Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: Preliminary results. Acta Hematol 1992, 87(Suppl.): 12-5.
156. Adusumilli, P.S., Chan, M.K., Hezel, M. et al. Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol 2007, 14(1): 258-69. (Pubitemid 44954297)
157. Stiles, B.M., Adusumilli, P.S., Stanziale, S.F. et al. Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. Int J Oncol 2006, 28(6): 1429-39.
158. Adusumilli, P.S., Stiles, B.M., Chan, M.K. et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg 2005, 80(2): 409-16.
159. Currier, M.A., Adams, L.C., Mahller, Y.Y., Cripe, T.P. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 2005, 12(4): 407-16.
160. Stanziale, S.R, Petrowsky, H., Adusumilli, P.S., Ben Porat, L., Gonen, M., Fong, Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anti-cancer activity. Clin Cancer Res 2004, 10(9): 3225-32.
161. Cameron, C., Hota-Mitchell, S., Chen, L. et al. The complete DNA sequence of myxoma virus. Virology 1999, 264(2): 298-318.
162. Toda, M., Martuza, R.L., Rabkin, S.D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000, 2(4): 324-9.
163. Liu, B.L., Robinson, M., Han, Z.Q. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003, 10(4): 292-303.
164. Weiss, G.R., Garnick, M.B., Osteen, R.T. et al. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol 1983, 1(5): 337-44.
165. Griffith, C., Noonan, S., Lou, E., Shillitoe, E.J. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Ther 2007, 14(12): 985-93.
166. Nakamura, H., Kasuya, H., Mullen, J.T. et al. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002, 109(7): 871-82.
167. Hu, J.C., Shorrock, J., Steiner, C., Love, R., Coffin, C. A phase I clinical trial with OncoVEX (GM-CSF). Proc Am Soc Clin Oncol (ASCO) 2003, 22. Abst 742.
168. Senzer, N.N., Kaufman, H.L., Amatruda, T. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009, 27(34): 5763-71.
169. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, Suppl.): Abst 6018.